Our exciting in vitro study results provide an impetus for testing HuR-FNP in vivo as monotherapy and as combinatorial therapy using conventional chemotherapeutics and molecularly targeted therapeutics for lung cancer. This evidence concerns the gene ELAVL1 and lung carcinoma.